Date : Since 05/09/2017
Place : Paris, August 2017Bioreagents
On August 2017, Bertin Pharma has signed an agreement for the sale of its pre-clinical and clinical studies’ activities.
CNIM Group, Bertin Pharma’s main shareholder, decided to focus on its strategic product ranges: providing Bioreagents & Bioanalytical Tools. Those markets are more in tune with its industrial core activities in the fields of energy, environment, defense and security.